StockData
Moderna, Inc. logo

Moderna, Inc. (MRNA) stock

MRNANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 5/30537% above fair value
$206.80−8.47 (-3.93%)

Close on Nov 17, 2026Market cap $82.56BP/E –Yield –

Moderna enterprise value

Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.

Moderna's enterprise value was $94.68B on Nov 11, 2026, against $5.65B a year earlier. Over the last 5 years it ranged from $3.92B to $94.68B, with a median of $32.10B.

Enterprise Value at the end of each year

PeriodPeriod endValueChange
2026Nov 11, 2026$94.68B+1247.5%
2025Dec 31, 2025$7.03B-23.1%
2024Dec 31, 2024$9.14B-69.8%
2023Dec 29, 2023$30.32B-50.4%
2022Dec 30, 2022$61.16B-34.9%
2021Dec 31, 2021$93.96B+147.1%
2020Dec 31, 2020$38.03B+598.4%
2019Dec 31, 2019$5.45B+2299.4%
2018Dec 31, 2018$226.93M–

More Moderna figures

See a number that looks wrong?